

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Antares Pharma, Inc.		02/26/2007	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MMV Financial Inc.		
<b>Street Address:</b>	95 Wellington Street West		
<b>Internal Address:</b>	22nd Floor		
<b>City:</b>	Toronto, Ontario		
<b>State/Country:</b>	CANADA		
<b>Postal Code:</b>	M5J 2N7		
<b>Entity Type:</b>	CORPORATION: CANADA		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	3150417	ANTARES PHARMA	
Registration Number:	0843292	MEDI-JECTOR	
Registration Number:	2412427	MEDI-JECTOR VISION	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(312)222-0818		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	312.222.0800		
<b>Email:</b>	lwdemarte@michaelbest.com		
<b>Correspondent Name:</b>	Luke W. DeMarte		
<b>Address Line 1:</b>	180 N. Stetson Avenue		
<b>Address Line 2:</b>	Suite 2000		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60601		
<b>ATTORNEY DOCKET NUMBER:</b>	019751-9003		

**OP \$90.00 3150417**

DOMESTIC REPRESENTATIVE

**900083233**

**TRADEMARK  
 REEL: 003592 FRAME: 0914**

Name:  
Address Line 1:  
Address Line 2:  
Address Line 3:  
Address Line 4:

NAME OF SUBMITTER:

Luke W. DeMarte

Signature:

/luke w. demarte/

Date:

07/30/2007

Total Attachments: 6

source=C0794060#page1.tif

source=C0794060#page2.tif

source=C0794060#page3.tif

source=C0794060#page4.tif

source=C0794060#page5.tif

source=C0794060#page6.tif

CONFIRMATION OF GRANT OF SECURITY INTEREST

This will confirm that, pursuant to a general security agreement (hereinafter referred to as the "GSA") dated February 26<sup>th</sup> 2007, between Antares Pharma, Inc., a corporation organized under the laws of the State of Delaware (hereinafter referred to as "Antares"), whose full post office address is 250 Phillips Blvd., Suite 290, Ewing, New Jersey 08618, U.S.A and MMV Financial Inc. (hereinafter referred to as "MMV"), a specialty finance corporation incorporated under the laws of Canada, whose full post office address is 95 Wellington Street West, 22nd Floor, Toronto, Ontario, M5J 2N7, as agent on behalf of itself and HSBC Capital (Canada) Inc., and for good and valuable consideration, the receipt and sufficiency of which are hereby confirmed and acknowledged, Antares confirms that it has granted to MMV a security interest, lien and charge in all of Antares' right, title and interest in and to the intellectual property listed on the Schedule attached hereto, including, without limitation, the copyrights, trademarks, patents and trademark and patent applications and registrations listed therein, and in and to any and all continuations, continuations-in-part, updates, developments, divisions, reissues and re-examinations which issue therefrom, the same to be held and enjoyed by MMV, strictly subject to the terms of the GSA.

EXECUTED at Ewing, NJ this 26<sup>th</sup> day of February, 2007.

ANTARES PHARMA, INC.

Per: 

Name: Jack E. Stover  
Title: President and Chief Executive  
Officer

I have authority to bind the Corporation.

**SCHEDULE TO INTELLECTUAL PROPERTY**

GOODMANSIARONSONG15405218.1

## INTELLECTUAL PROPERTY

### Patents

Title	Country	Filing Date	Expiration Date
USE OF AN ACRYLIC TYPE POLYMER AS DISINTEGRATING AGENT	UNITED STATES	07/15/1999	07/15/2019
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	UNITED STATES	03/07/2006	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	EUROPEAN PATENT CONVENT	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	JAPAN	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	CANADA	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	AUSTRALIA	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	NEW ZEALAND	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	MEXICO	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	BRAZIL	10/06/2004	10/06/2024
TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES	SOUTH AFRICA	10/06/2004	10/06/2024
PHARMACEUTICAL COMPOSITIONS OF NICOTINE AND METHODS OF USE THEREOF	UNITED STATES	07/24/2006	10/06/2024

Title	Country	Filing Date	Expiration Date
PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS	UNITED STATES	05/02/2005	05/02/2025
PERMEATION ENHANCED COMPOSITIONS FOR ANTICHOLINERGIC AGENTS	WIPO	05/03/2005	11/07/2006
METHODS AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	UNITED STATES	03/10/2004	03/10/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	EUROPEAN PATENT CONVENT	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	JAPAN	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	CANADA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	CHINA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	AUSTRALIA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	NEW ZEALAND	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	MEXICO	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	BRAZIL	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	SOUTH AFRICA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE	ISRAEL	03/11/2004	03/11/2024

Title	Country	Filing Date	Expiration Date
AGENTS			
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	INDIA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	SOUTH KOREA	03/11/2004	03/11/2024
USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	INDONESIA	03/11/2004	03/11/2024
NOVEL COMPOSITIONS FOR TRANSDERMAL AND/OR MUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS	UNITED STATES	05/19/2003	08/03/2021
METHODS OF TREATING HOT FLASHES WITH FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION	UNITED STATES	04/21/2006	04/21/2007
FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS	UNITED STATES	03/10/2004	08/03/2021
PERMEATION ENHANCER COMPRISING GENUS CURCUMA OR GERMACRONE FOR TRANSDERMAL AND TOPICAL ADMINISTRATION OF ACTIVE AGENTS	UNITED STATES	04/26/2005	04/26/2025
PERMEATION ENHANCER COMPRISING GENUS CURCUMA FOR TRANSDERMAL AND TOPICAL ADMINISTRATION OF ACTIVE AGENTS	WIPO	04/28/2005	
METHODS AND APPARATUS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF TESTOSTERONE	UNITED STATES	05/24/2006	05/24/2026
METHOD AND APPARATUS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF TESTOSTERONE	SOUTH AFRICA		
EUTECTIC COMPOSITION FOR ENHANCED TRANSDERMAL DRUG DELIVERY AND METHOD OF MAKING SAME	UNITED STATES	08/17/2006	08/17/2026

Title	Country	Filing Date	Expiration Date
LOW-FRIABILITY, PATIENT-FRIENDLY ORALLY DISINTEGRATING FORMULATIONS OBTAINED BY DIRECT COMPRESSION	UNITED STATES	02/17/2006	02/17/2007
TRANSDERMAL COMPOSITIONS OF PRAMIPEXOLE HAVING ENHANCED PERMEATION PROPERTIES	UNITED STATES	06/29/2006	06/29/2007
TRANSDERMAL COMPOSITIONS HAVING ENHANCED COLOR STABILITY	UNITED STATES	06/29/2006	06/29/2007

**Trademarks**

- Antares Pharma
- Medi-Jector
- Medi-Jector Choice
- Medi-Jector Vision

**Copyrights**

None.